Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0006142 (breast cancer)
 160,383 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Breast cancer incidence rates in Japan have more than doubled in the decade between 1975 and 1985 due to a well-established and affluent Western life-style. One hundred patients having breast cancer, 107 patients having mastectomies, and 243 patients having no breast cancer were reviewed for whole body and spot views of bone scintigraphy with 99mTc-MDP. The frequency of positive breast uptake in patients with no breast cancer showed a maximum in those patients between the ages of 30 and 40, with a progressive rise and fall before and after the peak, respectively. Patients between the ages of 50 and 60 with breast cancer showed a maximum uptake of 83%, while those patients between the ages of 70 and 80 with breast cancer showed an uptake higher than 50%. There was a markedly higher breast uptake ratio in the breast cancer group compared to the breast cancer free group. Although this scanning agent was of no value in recognition of tumor localization from breast uptake, we have to suspect a high incidence of cancer existence whenever there was unilateral increased breast activity. Even though the mechanism of 99mTc-MDP uptake by breast tissue is unknown, breast concentration of 99mTc-MDP appears to be influenced by hormones, especially estrogen.
 ...
PMID:[Visualization of the female breast in bone scintigraphy]. 146 59

Etidronate disodium (EHDP) therapy is often instituted emergently for treatment of hypercalcemia associated with malignancy, and a staging bone scan is part of the evaluation of the patient with extensive metastatic disease. In these patients in whom high dose EHDP therapy has been instituted, uptake of the bone scan agent is markedly diminished. The case presented illustrates this finding: a breast cancer patient who had received two 500-mg intravenous doses of EHDP prior to bone scan staging. No skeletal visualization was present at 3 hr after 99mTc-MDP injection. Blood-pool activity and uptake in large metastatic sites were observed.
 ...
PMID:Skeletal nonvisualization in a bone scan secondary to intravenous etidronate therapy. 156 85

This retrospective study aimed to assess the usefulness and clinical importance of current, commonly used, diagnostic staging procedures in breast cancer. The analysis comprises all 398 women clinically staged I-III (UICC criteria), and irradiated with radical intent in the Professorial Unit of Radiotherapy at the Middlesex Hospital over a ten-year period (1978-1987). The routine initial screening in this institution included the following staging investigations within 4 weeks of referral: 99mTc MDP bone scan; chest X-ray; liver function tests (including serum alkaline phosphatase) and liver ultrasound scan. Further enquiry and examination of the patient, clear progression of disease, additional radiographs or a recommended repeat interval scan provided sufficient additional information to confirm metastatic disease. The overall rate of detection of metastatic disease at three months was 29/389 (7.4%) for skeletal scintigraphy, 10/386 (2.6%) for chest radiographs, 8/271 (2.9%) for liver ultrasound and 3/347 (0.8%) for serum alkaline phosphatase. In total 37/398 (9.3%) of patients were confirmed to have metastatic disease by three months. Skeletal scintigraphy alone appears to identify 78% (29/37) of those with detectable metastatic disease at 3 months. Skeletal scintigraphy and liver ultrasound will identify 95% (35/37).
 ...
PMID:How far investigations for occult metastases in breast cancer aid the clinician. 203 84

It should first be stressed that the term BRM is wrong and unscientific, since this would include potassium cyanide or cancer chemotherapeutics in the strict sense of the term. Therefore, in this article we discuss the evaluation of Host Defence Potentiators (HDP). IL-2 or TNF should not be included as HDP because their action is local and not selective to cancer cells, similar to the case of cancer chemotherapeutics. IL-2 is not useful without the presence of IL-2-responsive cells in the host. The most important facet of the action of HDP is to increase the response of the host to cytokines or other bioactive substances according to the degree of maturation, differentiation or proliferation of responsive cells in the host defence mechanism. Lentinan appears to represent a unique class of HDP, markedly potentiating host resistance to cancer and bacterial, viral and parasitic infections, and shows prominent antitumor activity in syngeneic and autochthonous hosts, suppressing chemical and viral oncogenesis. The most important target of HDP is complete prevention of recurrence after "curative" surgery fundamentally through growth inhibition and regression of a small number of autochthonous tumor cells scattered in the host. Considering the excellent end-point results for phase III advanced and recurrent gastrointestinal and breast cancer, lentinan seems to be the most hopeful drug against cancer recurrence. The development of various new types of MDP mediating host homeostasis in the immune, endocrine and nervous systems and nutritional states is expected.
 ...
PMID:[Evaluation and consideration of BRM-BRM and HDP (host defense potentiators)]. 338 31

Radionuclide scanning is usually contraindicated in pregnancy because of the danger of fetal radiation exposure. Radionuclide bone scanning with Tc-99m MDP is a sensitive indicator of early osseous metastases in breast cancer. Three cases of breast cancer during pregnancy are reported; modified bone scanning was utilized for staging and decision analysis. Modifications of bone scanning techniques to minimize fetal radiation exposure and fetal dosimetry calculations are described.
 ...
PMID:Bone scanning in pregnant patients with breast carcinoma. 360 31

The occurrence of bone marrow carcinosis was investigated in 380 patients at the time of first recurrence of breast cancer. Results were related to results from radiographic bone survey, 99mTc MDP bone scintigraphy, clinical examination and serum alkaline phosphatase and serum calcium levels. Eighty-seven patients (23%) had tumor cells in the bone marrow. X-rays showed metastases in 78% of the patients with and in 16% of the patients without bone marrow carcinosis. The diagnostic efficiency of x-rays with bone marrow biopsy as the key diagnostic factor was 83%, and it was superior to that of other investigation methods. Bone tissue biopsies were positive alone in 15 patients (17%) and marrow aspirations were positive alone in seven patients (8%). Imprint preparations were positive alone in 7% of the patients and bone tissue biopsy in 5% of the patients. Heavy tumor infiltration (greater than or equal to 50%) of the bone marrow was associated with the occurrence of numerous regions of radiographically involved bone lesions and with histopathologic evidence of bone destruction. Furthermore, pronounced bone formation and marrow fibrosis were more commonly seen in patients with osteosclerotic bone metastases than in patients with osteolytic bone metastases. This study provides evidence that the primary soil of metastatic bone disease in human breast cancer is the bone marrow and that radiographic evidence of bone metastases is a result of an invasion and destruction of the bone tissue matrix by tumor cells from the marrow cavity.
 ...
PMID:The presence of tumor cells in bone marrow at the time of first recurrence of breast cancer. 362 Nov 13

A 51-year-old female presented herself with complaints of mis-swallowing, hoarseness, speech disturbance and right stiff shoulder of 3 months duration. She had left breast cancer operated on elsewhere 10 years previously. Pertinent neurological findings were 9th, 10th, 11th and 12th cranial nerve palsies on the right (the Collet-Sicard syndrome). Cerebral angiography, retrograde jugular venography, polytomography of the skull base and bone scintigraphy with 99mTc-MDP raised a question of metastasis of the breast cancer to the skull base of the right mastoid region. Following right retromastoidal suboccipital craniectomy, partial removal of the metastatic skull tumor of the deep mastoid region was done. No intracranial extension of the tumor was confirmed. Multiple cranial nerve palsies above mentioned resolved following irradiation with betatron of 5000 rads. Pathology report was that of metastatic adenocarcinoma to the skull, which was similar to the histology of the breast cancer resected 10 years previously. Skull base metastasis of the breast cancer causing the Collet-Sicard symdrome is rare. To the author's knowledge, only 7 cases of the Collet-Sicard syndrome caused by metastatic tumors have been reported in the English and Japanese literatures. Primary lesions were as follows: The one was from the lung and the rest were all from the prostate. We are reporting the first case of the Collet-Sicard syndrome due to metastatic adenocarcinoma of the breast to the skull base.
 ...
PMID:[Skull base metastasis of the breast cancer causing the Collet-Sicard syndrome--a case report (author's transl)]. 740 20

Progressive diaphyseal dysplasia was incidentally discovered in two patients referred for Tc-99m MDP bone scintigraphy (one for intense sciatica, the other for the detection of breast cancer metastases). Tracer accumulation in the diaphyses of the lower limbs and the base of the skull was accompanied by bone thickening and patency of the medullary cavity, as demonstrated by radiography, MRI, and bone marrow scanning. Comparison of the clinical pictures with the results of instrumental examinations showed that these were cases of sporadic progressive diaphyseal dysplasia of slight and average gravity, respectively. The differentiation of Ribbing's disease is explained and reference also is made to a finding not mentioned in the literature, namely frontal bone resorption lacunules in one patient.
 ...
PMID:Correlation between bone imaging and the clinical picture in two unsuspected cases of progressive diaphyseal dysplasia (Engelmann's disease). 848 29

Although bone scintigraphy using Tc-99m labelled diphosphonates is a highly sensitive modality for the detection of of the extent of secondary skeletal malignancies, it is often not sufficient since possible bone marrow participation cannot be imaged We make a preliminary report on the usefulness of bone marrow immunoscintigraphy in the follow-up of patients with skeletal metastases due to breast and prostate cancer in parallel with the interpretation of conventional Tc-99m MDP bone scans. Approximately 7 to 9 months after radionuclide therapy both Tc-99m MDP [Hellenic Nuclear Research Center "Democritos". Aghia Paraskevi, Attikil and Tc-99m Anti-Granulocyte BW 250/183 [CIS Bio International, Gif sur Yvette, France] bone scans were performed on 2 prostate cancer patients and 5 women with breast cancer with disseminated bone metastases. Bone scans preceded bone marrow scans. Bone marrow defects were concordant with cortical scans in 4 cases, while they were larger in 4 sites compared to -MDP scan. Four sites in the ribs, shown on -MDP scan could not be detected on antigranulocyte scans. Bone cortex and marrow combined imaging of osseous metastases using different radiotracers increases the information on the real extent of skeletal involvement; the scintigraphic data obtained are valuable for the further decision making for the best possible management of unexpected myelosuppressive side effects as well as the follow-up of the treated cancer patients.
 ...
PMID:99mTc-antigranulocyte bone marrow scintigraphy of breast and prostate skeletal metastases. 917 4

In bone scintigraphy extraosseous uptake of the radiopharmaceutical (TcO4-, pertechnetate) is a common finding when the stomach is abnormally observed; this may be due to the instability of the radiopharmaceutical leading to free pertechnetate within this organ. The same explanation might be inculpate rhenium 186-HEDP, due to its similarity to Tc-99m MDP's sphysicochemical properties and behavior, as both radioisotopes are Group VII metals /1/ and are labelling the same ligand (a diphosphonate moiety). We report on 186Re-HEDP uptake in the stomach in two patients with osseous metastases because of prostate and breast cancer respectively out of a series of 52 cancer affected individuals, treated with 186Re-HEDP. The thorough clinical and laboratory investigation of both patients assessed that this extraosseous radio-rhenium accumulation was multifactorial with the main cause being a disturbance of body fluid acid-balance, favoring calcium and phosphate ion precipitation and leading to 186Re-HEDP extraosseous uptake.
 ...
PMID:Gastric uptake during Re-186 HEDP bone scintigraphy. 917 34


1 2 3 4 Next >>